Liquisolid Formulations Research Articles

Formulation, Optimization and Evaluation of Ticagrelor Liquisolid Tablets for Enhanced Solubility

Purpose The study aims to use liquisolid compacts technology as a novel carrier to enhance Ticagrelor's solubility and release profile. Method: Formulation of liquisolid tablets was developed using the Design of Experiment (DOE) approach where the drug Ticagrelor was dispersed in PEG-600 and incorporated into carrier material (Neusilin US2) in the mortar, the liquid drug was permitted to absorb in the second stage. Aerosil-200 was used as a coating material, and Magnesium stearate and Sodium starch Glycolate were used as Lubricant and Disintegrating Agent respectively. The formulations were optimized and the carrier-to-coating ratio and mixing Aerosil-200 with Neusilin US2 effect on drug release from the formulation was investigated. The prepared liquisolid compacts were subjected to micrometric characterization, post-compression parameters, Fourier Transform Infrared Spectroscopy (FTIR), and Differential Scanning Calorimetry (DSC). Result: The cumulative drug release of all formulations in dissolution media varies from 82% to 96% and Formulation F9 showed a maximum cumulative drug release of about 96%. The drug contents of all formulations ranged from 91.06% to 99.01%. Disintegration time for all 1-9 formulations, clearly, all compositions disintegrate in less than 10 minutes. The cumulative drug release of all formulations varies from 82% to 96% Formulation F9 showed a maximum cumulative drug release of about 96% and the conventional tablet showed a cumulative drug release of about 80 %. The optimized liquisolid formulation F8 outperformed the other batches in terms of flow and compressibility across all formulations. Conclusion: Therefore, as per the results, it can be inferred that Ticagrelor, when formulated by a liquisolid approach, produce ameliorated dissolution and stability profile.

Liquisolids: A Modernistic approach in Drug Delivery System

Liquisolid Technology aims to make drug entities more soluble that have low solubility and low permeability, through the cosolvency theory in a reasonably simple setup that doesn't require expensive technology. A non-volatile solvent is used to dissolve a medicine into molecular dispersion, which is then converted into a powder that has the appearance of being dry and is easily compressible. Extrudates are produced from the material by extrusion using an extruder. To create spherical particles known as Pellets, the extrudates are placed beneath the spheronizer. These pellets or granules can be filled in capsules or can be compacted into tablets according to their dose and can be utilized. Various evaluation parameters like Carr`s Index, Angle of Repose, FTIR, etc was studied. Overall, the study demonstrated that the liqui-pellet might improve a liquisolid formulation's poor flowability, which is thought to be a significant development in the concept's commercial viability. The current review aims to unfurl the utilization of liquisolid technology as a potential drug delivery system for BCS class 2 and 3 drugs.

Novel Approaches to Enhance Solubility Medicine

The solubility enhancement of poorly aqueous soluble drugs presents a significant challenge in pharmaceuticalformulation. Liquisolid technology, also known as powdered solution technology, has emerged as a promising approach toenhance the solubility and bioavailability of such drugs. This paper provides a detailed discussion of the novel approachesemployed within the framework of Liquisolid technology to overcome solubility limitations. The study explores the principles,advantages, and applications of Liquisolid technology in drug formulation, highlighting its potential to revolutionize oralmedication delivery. This research aims to investigate the effectiveness of Liquisolid technology in enhancing drug solubility,elucidate its underlying mechanisms, and evaluate its impact on drug dissolution, bioavailability, and therapeutic outcomes. Theobjectives are to review the background and challenges associated with poor solubility of drugs, introduce the concept ofLiquisolid technology and its principles, discuss the advantages and benefits of Liquisolid technology in solubility enhancement,explore the formulation strategies and key components involved in Liquisolid formulations, evaluate the in vitro and in vivoperformance of Liquisolid systems, and identify future research directions and potential applications of Liquisolid technology inpharmaceutical development. Through this comprehensive analysis, the study aims to provide valuable insights into the novelapproaches based on Liquisolid technology for enhancing drug solubility, facilitating the development of effective and efficientdrug delivery systems. Liquisolid technology, a novel approach to solubility enhancement, offers promising advantages overconventional techniques. It involves solubilizing poorly aqueous soluble drugs using surfactants, then incorporating thesesolubilized drugs into a carrier system or powdered solution. The powdered solution facilitates the conversion of the solubilizeddrug into solid residues, which can be further processed into different dosage forms.

Liqui-pellets as a Novel Approach in the Formulation of Oral Solid Products

In dosage form design, rather particular interest is shown towards solid oral products as they are versatile and highly preferred by the pharmaceutical manufacturing industry. To tackle poor dissolution and bioavailability of problematic drugs, liquisolid technology is developed, from which further advances like liqui-pellet's originated. The latter requires lower economic investment than the liquisolid formulation technology. Some limitations in the liquisolid technology are inadequate flowability, compressibility and the inability to manufacture high-dose oral products, which are very difficult to administer. Overall, the liqui-pellets would overcome the inadequate flowability of the liquisolid formulation adding a better drug release ability. These problems can be resolved by employing the liqui-pellets. This review article provides information about liqui-pellets' advantages, the preparation method, factors affecting them and evaluation studies. The main background areas like liquisolid technology, extrusion and spheronization technology are also discussed. The liqui-pellet system is a significant innovation in oral solid drug products.

Development of Doxazosin mesylate liquisolid system for improved manufacturing processability and bioavailability: in vitro and in vivo evaluation for tailored hypertension treatment approach with modified dissolution rates

In the present research, an attempt was made to optimize the blends of different carriers Neusiln US2, Avicel PH101, and Fujicalin SG by individually blending with each of coating materials Aerosil 200 and Syloid 244 FP that were proposed to contribute to a modified drug dissolution rates of Doxazosin mesylate (DX) through a liquisolid polymer matrix system. The liquisolid formulations were prepared using selected solvent, carriers, and coats by varying drug to polymer ratios. Further formulations were investigated for pre-compression processability by Heckel plot analysis, elastic recovery studies, and post-compression characteristics. In case of carriers, compared to Avicel PH101 highest flowable values (ф) were observed for Neusilin US2 and Fujicalin SG whereas, for coat these values were highest for Aerosil 200 than Sylloid 244 FP. Liquisolid compact with Fujicalin SG and Aerosil 200 exhibited fast release (FR) of 78% in 20 minutes. The liquisolid compact with Neusilin US2 and Syloid 244 FP exhibited prolonged release (PR) of 60% in 240 minutes. DSC and XRD analysis showed loss of DX crystallinity which was confirmed by SEM analysis indicating DX detention within the liquisolid system, in a molecularly dispersed solubilized form. The in vivo studies of DX liquisolid FR formulation exhibited 1.89 fold increase in the oral bioavailability which was 1.69 fold for DX PR formulation compared to pure DX which demonstrated a promising tailored hypertension treatment approach.

Quality by design-oriented formulation optimization and characterization of guar gum-pectin based oral colon targeted liquisolid formulation of xanthohumol

Quality by design-oriented formulation optimization and characterization of guar gum-pectin based oral colon targeted liquisolid formulation of xanthohumol

Solubility Enhanced Formulation Approaches to Overcome Oral Delivery Obstacles of PROTACs.

PROteolysis TArgeting Chimaeras (PROTACs) offer new opportunities in modern medicine by targeting proteins that are undruggable to classic inhibitors. However, due to their hydrophobic structure, PROTACs typically suffer from low solubility, and oral bioavailability remains challenging. At the same time, due to their investigative state, the drug supply is meager, leading to limited possibilities in terms of formulation development. Therefore, we investigated the solubility enhancement employing mini-scale formulations of amorphous solid dispersions (ASDs) and liquisolid formulations of the prototypic PROTAC ARCC-4. Based on preliminary supersaturation testing, HPMCAS (L Grade) and Eudragit® L 100-55 (EL 100-55) were demonstrated to be suitable polymers for supersaturation stabilization of ARCC-4. These two polymers were selected for preparing ASDs via vacuum compression molding (VCM), using drug loads of 10 and 20%, respectively. The ASDs were subsequently characterized with respect to their solid state via differential scanning calorimetry (DSC). Non-sink dissolution testing revealed that the physical mixtures (PMs) did not improve dissolution. At the same time, all ASDs enabled pronounced supersaturation of ARCC-4 without precipitation for the entire dissolution period. In contrast, liquisolid formulations failed in increasing ARCC-4 solubility. Hence, we demonstrated that ASD formation is a promising principle to overcome the low solubility of PROTACs.

Fabrication and characterization of Orlistat Liquisolid tablets

The aim of the work was to improve the dissolution properties of the practically insoluble anti-obesity drug, Orlistat by utilizing liquisolid technique. Different liquisolid tablets were prepared by dissolving Orlistat in PG with Avicel PH 102 as carrier, Aerosol 200 as coating material and Sodium starch glycolate as disintegrating agent. Additives such as PVP, HPMC and HPG were incorporated into the formulations to improve dissolution characteristics. The formulated liquisolid tablets were evaluated for post compression parameters such as weight variation, hardness, friability, drug content and in-vitro dissolution studies. FT-IR study suggested that there was no chemical interaction between the drug and excipients. DSC was performed to evaluate the physicochemical properties of the liquisolid tablets, which confirm the conversion of crystalline form of the drug to the amorphous form in liquisolid tablets. The result showed that liquisolid formulation of Orlistat exhibited higher percentage of drug release than directly compressed tablets which show significant benefit of liquisolid tablet in increasing wetting properties and surface area of drug available for dissolution.

Validated high‐performance thin layer chromatographic method for simultaneous quantification of rifampicin and quercetin in liquisolid formulation using fractional factorial design in robustness study

AbstractThe present research study focuses on the development of the high‐performance thin‐layer chromatographic method using the design of experiment approach for the simultaneous estimation of Rifampicin and Quercetin. Chromatographic separation was performed on Aluminium plates precoated with silica gel 60 F254 using chloroform:methanol:formic acid:ethyl acetate:benzene (4:1.8:0.3:1.7:1, v/v/v/v/v) as optimized mobile phase. A fractional factorial design was applied for the robustness study and the independent variables selected were mobile phase composition (A), solvent front (B), chamber saturation time (C), and wavelength (D). It was statistically revealed that the volume of ethyl acetate affected the Rf of both drugs resulting in stricter control of ethyl acetate volume compared to the other three variables. Rf for Rifampicin and Quercetin was 0.35 and 0.71 at 347 nm. The linear concentration range was 100–600 ng/band for both drugs. The %recovery ranged between 95.25% and 96.71% for Rifampicin and 95.33%–96.86% for Quercetin. The method was validated by determination of linearity, precision, accuracy, and specificity according to Q2(R1) guidelines, and the %relative standard deviation values were less than 2% for both drugs. A simple, accurate, and reproducible high‐performance thin‐layer chromatographic method was developed, for routine quality control testing of pharmaceutical formulation.

Design and Development of Solid SMEDDS and Liquisolid Formulations of Lovastatin, for Improved Drug Dissolution and In vivo Effects-a Pharmacokinetic and Pharmacodynamic Assessment.

Lovastatin (Lov) is a lipid-lowering agent, with 5% bioavailability (BA) due to extensive first pass metabolism and poor solubility. To enhance dissolution and in vivo effects, Lov solid self microemulsifying drug delivery system (SMEDDS) and liquisolid systems were developed and evaluated to select superior one. Solubilities were determined in oils, surfactants, and cosurfactants. Ternary phase diagrams were constructed and selected the one which showed maximum emulsion zone. In vitro dissolution, DSC, SEM and PXRD studies were used to characterize the developed formulations. In vivo studies were conducted on optimal formulations in wistar rats. Based on solubilities, Capmul PG8 and Capmul MCM were preferred as oils, Labrasol and Transcutol P as surfactant and cosurfactant. Here, Syloid XDP carrier showed better adsorption capacity among others, hence was used in optimal solid SMEDDS (SX) and liquisolid (LS) formulations. Dissolution study results showed significant improvement in release when compared to pure drug. DSC, SEM, and PXRD results indicated the loss of drug crystallinity in optimal formulations. In pharmacokinetic (PK) study, SX and LS showed 2.57 and 1.43 fold improvements in AUC, when compared to that of coarse suspension (CS). In pharmacodynamic (PD) study, hyperlipidemia was induced by Triton X-100. CS and LS treatments showed a decline in hyperlipidemic levels at 4h. But, SX-treated group showed early onset of decline at 2h. Further, the duration of anti-hyperlipidemia was at least 12h extra when compared to CS and LS. This study confirmed the superiority of SX over LS in PK and PD effects.

Combining Liquisolid and Co-grinding Techniques to Enhance the Dissolution Rate of Celecoxib

PurposeThe classic liquisolid technique is used to enhance the dissolution rate of poorly water-soluble drugs, but in some cases, it is impossible to reach the desired dissolution rate using this technique alone. Therefore, a novel approach using a combination of ball milling and liquisolid technology was investigated to improve the dissolution rate for celecoxib.MethodsFirst, celecoxib was dispersed in a liquid vehicle (PEG 200), then ground in a ball mill for 3 h. Other excipients, including PVP, microcrystalline cellulose as the carrier powder, and silica as the coating material, were added to the mortar. Dissolution testing was carried out in simulated intestinal fluid (SIF) and simulated gastric fluid (SGF) media. The effects of aging on the hardness and dissolution profile were also studied. X-ray diffraction (XRD) and differential scanning calorimetry (DSC) was used to identify changes in the crystallinity or complex formation.ResultsThe novel formulations showed a higher dissolution rate than the conventional tablet or classic liquisolid formulations. Aging did not affect the hardness and dissolution profiles of the liquisolid compacts. The DSC and XRD results suggested that the enhanced dissolution rate is not caused by the formation of any complexes and reduction in crystallinity degree may contribute to the dissolution enhancement. The enhanced dissolution rate is attributed to the elevated specific surface area of the drug in the liquisolid state.ConclusionThe results showed that liquisolid technology combined with ball milling is an efficient tool for enhancing the dissolution of poorly water-soluble drugs.

Investigating the use of Liquisolid Compact Technique for Pioglitazone HCl

The aim of present study is to enhance the dissolution of poorly water soluble drug of Pioglitazone HCl by liquisolid compact technique. Liquisolid compact were prepared using propylene glycol as non-volatile solvent, Avicel PH102 as carrier and Aerosil 200 as coating material, sodium starch glycolate as superdisintegrant.The compatibility of excipients and drug was confirmed by FT-IR studies. The dissolution studies for prepared liquisolid tablet were distinctly higher as compared to directly compressed tablets which show significance increased in wetting properties and surface area of drug available for dissolution. The optimized PIO-7 liquisolid formulation shows acceptable flow properties, faster disintegration time and superior dissolution profile. The optimized formulation of liquisolid pioglitazone tablet shows higher drug release when compared to marketed formulation. The mechanism of drug release studied for best formulations where fitted in accordance with higuchi model and korsemeyer peppas model it is evident that a linear relationship was obtained showing that is an apparent first order process.

APPLICATION OF LIQUISOLID SYSTEMS IN MODIFYING DRUG RELEASE OF GLICLAZIDE

Liquisolid technique is an emerging technology of formulation development. In the present work, a modified-release formulation of gliclazide was developed by using the liquisolid technique. Gliclazide was dispersed in a nonvolatile solvents system of Tween 80 and propylene glycol, followed by adsorbing the liquid medication on carrier material MCC pH 102. Drug release rate controlling polymer HPMC was wet granulated with binder solution along with diluent. The two blends of API liquisolid and polymer mixture were blended uniformly with extra granular excipients to manufacture gliclazide modified release tablets 30 mg. Characterization of gliclazide liquisolid tablets was done using analytical techniques, i.e., FTIR and XRD. The optimization of the formulation was done by using mixture design where the amount of propylene glycol, Tween 80, DCP (anhydrous), HPMC K4M and HPMC K100 LVCR were considered to be the independent formulation variables. The dissolution and hardness were considered as dependent variables. The formulations were evaluated for dissolution, assay, hardness, thickness and other vital properties. The liquisolid formulation showed a zero-order release pattern and matched with the innovator (Diamicron MR 30 mg). The modified release tablets showed good stability at 40 °C / 75% RH for three months.

Enhancement of ketoprofen dissolution rate by the liquisolid technique: optimization and in vitro and in vivo investigations.

The objective of the current study is to evaluate the prospective of liquisolid formulation to improve the dissolution rate of ketoprofen and thereby the bioavailability. Different batches of liquisolid were prepared using polyethylene glycol 200 as a solvent, microcrystalline cellulose, and aerosil 200 as carrier and coating material, respectively. Central composite design (32) was utilized to examine the effects of independent variables (load factor and excipient ratio) on dependent variables (solubility and % in vitro drug release). Differential scanning calorimetry, Fourier transform infrared spectroscopy, X-ray diffraction, and scanning electron microscopy techniques were employed for characterization of optimized batch (LS-10) of liquisolid formulation. The half-maximal inhibitory concentration (IC50) values for in vitro anti-inflammatory activity for liquisolid formulation exhibited a higher anti-inflammatory effect than ketoprofen and physical mixture. The statistical analysis of in vivo (anti-inflammatory and analgesic) activities data demonstrated that the test (optimized formulation) treatment group resulted in quick pharmacological response in Wistar rats and Albino mice when compared with standard (pure drug) and control treatment groups. The results obtained in the present study illustrated that the liquisolid formulation could be a propitious approach to increase the bioavailability of ketoprofen and could be used in oral therapy.

Design and development of fast dissolving liquisolid formulation

Various techniques have been employed for the solubility modification of BCS class II drugs. Out of the recent solubility enhancement techniques, Liquisolid technique based on the work of Spireas et al has explored as method that can supplement drug release. Formulations containing Etodolac were developed by dissolving the drug in a non-volatile solvent and then employing the adsorption absorption principle with a carrier and coated material admixture. The post formulation saturation solubility study has highlighted significant modification in solubility of the drug in comparison to pre solubility modification. The Liquisolid formulation then subjected to direct compression for the development of Fast dissolving tablet formulation using two varying concentrations of Sodium Starch Glycolate. The in vitro - in vivo evaluation of research study concludes adaptability and applicability of fast dissolving liquisolid tablet formulation allowing it to overcome barriers associated with the solubility. The optimized formulation found to unveil dissolution along with diffusion from the dosage form by Fickian mechanism. Keywords: Etodolac, Liquisolid, Carrier material, Coating material Fast dissolving tablet, Superdisintegrant.

Formulation and Optimization of Rifampicin and Quercetin Laden Liquisolid Compact: In-Vitro and In-Vivo Study

The major objective of this study is to create rifampicin and quercetin-containing liquisolid compacts with improved gastrointestinal absorption and dissolving properties. Propylene glycol, PEG 200, and Tween 20 were chosen as ideal non-volatile liquid carriers to create the required formulations because of their increased drug solubility. In an attempt to create a free-flowing, compressible powder, the liquisolid formulations were then combined with a carrier and coating material. In order to c

A Short Review on Application of Liquisolid Technology

In this paper we have surveyed about formulation and evaluation of Liquisolid formulations and its work in antidiabetics . Mostly poorly water soluble drugs are in research category despite of less dissolution rate and poor bioavailability. Solubility is a vital parameter to develop new formulation as industries faced serious issue regarding the poor aqueous solubility of the drugs. Various methods for solubility enhancement include modifications of the drug, involvement of co-solvents, complexation, salt formation, size reduction. A propitious technique to solve major challenges like solubility, dissolution rate and their bioavailability. This technique can be defined as the conversion of poorly soluble liquid medications into non-adherent, dry, compressible and free flowing powder mixtures with help of excipients. Many anti-diabetic drugs are belonging to BCS Class-II facing challenges like solubility and bioavailability.

Development, Characterization, and Optimization of a Novel Abiraterone Acetate Formulation to Improve Biopharmaceutical Attributes Aided by Pharmacokinetic Modelling

Abiraterone acetate has very low bioavailability and drastic food effect to warrant a dosing regimen under fasting state only. Therefore, we aimed to develop and optimize a liquisolid compact formulation of abiraterone acetate to improve biopharmaceutical attributes aided by pharmacokinetic modelling and achieve dose reduction with no food effect on the formulation. Preliminary studies highlighted the importance of the selection of olive oil as a compatible vehicle. The pharmacokinetic model, integrated with gastrointestinal physiology, was used to predict fasted and fed state pharmacokinetic parameters. Optimization of the liquisolid formulation containing abiraterone acetate was carried at more than five times lower dose, i.e. 190 mg, compared to 1000 mg. A central composite design (CCD) was used to identify optimal levels of formulation factors, namely the amount of vehicle (olive oil), the amount of coating agent (silicon dioxide), and the amount of surfactant (polysorbate 80). Graphical optimization using the selected models in conjunction with maximization of the desirability was used to identify the optimized liquisolid formulation. The predicted pharmacokinetic parameters (fasted Cmax 901.83ng/mL, fasted AUCinf 2723.82 ng·h/mL, fed Cmax 1024.34 ng/mL, and fed AUCinf 3041.83ng·h/mL) of the optimized formulation were acceptable. Overall, the liquisolid compact formulation of abiraterone acetate was successfully developed and optimized. In vitro solubility and dissolution results aided by pharmacokinetic modelling also showed improved predicted bioavailability with greater than five times reduction in dose and elimination of food effect.

Improvement of The Photostability of Nimodipine by Using Liquisolid Compacts Technique

Liquisolid compacts are one of the modern drug formulation techniques used for drug formulation for several objectives including protection against photosensitivity. This study evaluates the photoprotective effect of the liquisolid compact technique on a calcium channel blocker antihypertensive drug, nimodipine, which is considered a photosensitive drug model. Liquisolid compact tablets of nimodipine were prepared from; Avicel PH-102 as a carrier material, (colloidal silicon dioxide, Cab-O-sil, and titanium dioxide as coating materials), croscarmellose sodium (CSS), sodium starch glycolate (SSG), crospovidone (CP) as super disintegrants, and propylene glycol as the liquid vehicle. However, the ratio of carrier to coating materials was kept constant in all formulations at 35:1. This ratio was chosen after testing the ratios 15:1, 20:1, 25:1, 30:1 and 35:1. The feasibility of the prepared liquisolid systems was also evaluated for first; the pre-compression and post-compression characteristics. Second, the possible drug-excipients interaction using FT-IR. Third, the photostability of Nimodipine in pure form, conventional tablets, and in the prepared liquisolid tablets through irradiation with a light dose of 0.55 W/m2/h visible light, 50 W/m2/h UVA and 0.27 W/m2/h UVB for 12 h in order to estimate the effect of coating material type on Nimodipine stability especially in the prepared liquisolid formulations. The results showed that all of the prepared liquisolid tablets showed satisfactory properties regarding pre and post-compression properties. Interestingly, the FTIR spectra study ruled out any interaction between nimodipine and excipients in the prepared liquisolid tablets. Besides, all of the prepared liquisolid tablets had shown a superior drug dissolution profile compared to the conventional and direct compressed tablets. Finally, 92.43% of the drug remaining was found in the liquisolid formulation (F7) after 12 h photo-irradiation as compared to 65.48% drug remaining for the pure drug substance and 75.12% for directly compressed tablets indicating that liquisolid technique had significantly inhibited the photo-degradative effect of light in the prepared liquisolid formulations. It can be concluded that the liquisolid compacts technique is a promising approach for the improvement of photostability of this photosensitive Nimodipine with an acceptable stability as well as enhanced dissolution rate.

Formulation and Evaluation of Liquisolid Compacts of BCS Class II Drug Ketoprofen

Aims: The main objective of the current research work is to develop liquisolid compacts of BCS Class II drug ketoprofen with an intention to enhance the solubility of drug by applying liquisolid technique.
 Place and Duration of Study: Smriti College of Pharmaceutical Education between June 2018 June 2019.
 Methodology: Initially liquid medication was obtained by dissolving drug in suitable solvent. Saturation solubility studies were performed in various hydrophilic non-volatile solvents to select the solvent showing highest solubility for drug. This liquid medication was admixed with calculated amounts of carrier material (Avicel PH 102) and coating material (Cab-O-Sil) using Spireas mathematical model in order to obtain liquisolid formulations. Further, this powder mass of liquisolid system was compressed to form Ketoprofen liquisolid compact formulations ranging from TK1 to TK9. They were further subjected to post compression evaluation tests such as weight variation, hardness, friability, content uniformity, disintegration and in vitro dissolution studies.
 Results: Based on the solubility studies, PEG 400 was selected as solvent for ketoprofen drug. Rheological properties for the prepared liquisolid powder system were performed for all the formulations and they showed acceptable flow properties. The results obtained for the post compression evaluation tests of all the prepared liquisolid compacts were present within the acceptable limits. The disintegration time observed for all formulations were within 5 minutes. The results of in vitro release of all the liquisolid compacts showed enhanced release rates compared to that of directly compressed tablet. Lquisolid compact formulation TK7 showed maximum release of 97.62% of drug within 12 minutes in pH 7.4 phosphate buffer which was much higher when compared to that of directly compressed tablet. The SEM and PXRD studies for TK7 revealed conversion of crystalline to molecularly dispersed form of drug in the obtained liquisolid formulation. DSC and FTIR studies also revealed that there was no presence of any significant interaction between drug and excipients involved in the formulation.
 Conclusion: Finally, it could be concluded that Liquisolid technique was successful in enhancing the solubility and further dissolution profile of BCS Class II drug Ketoprofen.